SB-269970 |
カタログ番号GC37599 |
SB-269970 は、pKi が 8.3 の、強力で選択的な脳浸透性の 5-HT7 受容体拮抗薬です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 201038-74-6
Sample solution is provided at 25 µL, 10mM.
SB269970 is a 5-HT7 receptor antagonist with pKi of 8.3, exhibits >50-fold selectivity against other receptors. pKi: 8.3 (5-HT7 receptor)[1]
SB-269970 (3-30 mg/kg; i.p.; once) significantly blocks amphetamine and ketamine-induced hyperactivity[2]. Animal Model: male C57BL6/J mice[2]
[1]. Hagan JJ, et al. Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol. 2000 Jun;130(3):539-48. [2]. Roberts C, et al. The effect of SB-269970, a 5-HT(7) receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. Br J Pharmacol. 2001 Apr;132(7):1574-80. [3]. Nikiforuk A, et al. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One. 2013 Jun 11;8(6):e66695. [4]. Monti JM, et al. The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat. Behav Brain Res. 2008 Aug 22;191(2):184-9.
Average Rating: 5
(Based on Reviews and 2 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *